ABO-incompatible kidney transplantation using immunoadsorption columns: First experiences in South Africa.

IF 1.5 4区医学 Q2 MEDICINE, GENERAL & INTERNAL Samj South African Medical Journal Pub Date : 2024-04-24 DOI:10.7196/SAMJ.2024.v114i3b.1326

Z A Barday

{"title":"ABO-incompatible kidney transplantation using immunoadsorption columns: First experiences in South Africa.","authors":"Z A Barday","doi":"10.7196/SAMJ.2024.v114i3b.1326","DOIUrl":null,"url":null,"abstract":"Background: ABO-incompatible kidney transplantation gives patients with chronic kidney disease requiring dialysis and without a blood group-compatible donor an alternative option for a kidney transplant.Objectives: To describe our first experiences and outcomes with 3 patients using Glycosorb ABO immunoadsorption (IA) columns in performing ABO-incompatible living-donor kidney transplants. This is the first time this technique has been used in Africa.Methods: As per the protocol, patients needed between 1 and 4 sessions of IA and received rituximab ~ one month before transplantation.Results: All the patients achieved the target isohaemagglutinin antibody titre of 1:4 pretransplant. Only 1 patient with the highest initial screening titre (1:256) needed IA post-transplant. None of the patients experienced clinical rejection, and all had good graft kidney function at discharge and at the time of writing.Conclusion: Glycosorb ABO IA is an effective technique in enabling ABO-incompatible living-donor kidney transplants to be performed successfully in a South African setting.","PeriodicalId":49576,"journal":{"name":"Samj South African Medical Journal","volume":"114 3b","pages":"e1326"},"PeriodicalIF":1.5000,"publicationDate":"2024-04-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Samj South African Medical Journal","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.7196/SAMJ.2024.v114i3b.1326","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"MEDICINE, GENERAL & INTERNAL","Score":null,"Total":0}

引用次数: 0

Abstract

Background: ABO-incompatible kidney transplantation gives patients with chronic kidney disease requiring dialysis and without a blood group-compatible donor an alternative option for a kidney transplant.

Objectives: To describe our first experiences and outcomes with 3 patients using Glycosorb ABO immunoadsorption (IA) columns in performing ABO-incompatible living-donor kidney transplants. This is the first time this technique has been used in Africa.

Methods: As per the protocol, patients needed between 1 and 4 sessions of IA and received rituximab ~ one month before transplantation.

Results: All the patients achieved the target isohaemagglutinin antibody titre of 1:4 pretransplant. Only 1 patient with the highest initial screening titre (1:256) needed IA post-transplant. None of the patients experienced clinical rejection, and all had good graft kidney function at discharge and at the time of writing.

Conclusion: Glycosorb ABO IA is an effective technique in enabling ABO-incompatible living-donor kidney transplants to be performed successfully in a South African setting.

查看原文

微信好友朋友圈 QQ好友复制链接

本刊更多论文

使用免疫吸附柱进行 ABO 不兼容肾移植：南非的首次经验。

背景：ABO血型不相容肾移植为需要透析但没有血型相容供体的慢性肾病患者提供了另一种肾移植选择：描述我们首次使用Glycosorb ABO免疫吸附（IA）柱为3名患者进行ABO血型不相容活体供肾移植的经验和结果。这是非洲首次使用这种技术：根据方案，患者需要进行 1 到 4 次 IA，并在移植前一个月接受利妥昔单抗治疗：结果：所有患者在移植前都达到了异血凝素抗体滴度 1:4 的目标。只有一名初次筛查抗体滴度最高的患者（1:256）需要在移植后接受IA治疗。所有患者均未出现临床排斥反应，出院时和撰写本文时移植肾功能良好：Glycosorb ABO IA是一种有效的技术，可使ABO不相容的活体供肾移植在南非环境中成功进行。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文去求助

来源期刊

Samj South African Medical Journal 医学-医学：内科

CiteScore

3.00

自引率

4.50%

发文量

175

审稿时长

4-8 weeks

期刊介绍： The SAMJ is a monthly peer reviewed, internationally indexed, general medical journal. It carries The SAMJ is a monthly, peer-reviewed, internationally indexed, general medical journal publishing leading research impacting clinical care in Africa. The Journal is not limited to articles that have ‘general medical content’, but is intending to capture the spectrum of medical and health sciences, grouped by relevance to the country’s burden of disease. This will include research in the social sciences and economics that is relevant to the medical issues around our burden of disease The journal carries research articles and letters, editorials, clinical practice and other medical articles and personal opinion, South African health-related news, obituaries, general correspondence, and classified advertisements (refer to the section policies for further information).